13 March 2019 - With public and political winds blowing in the same direction, significant reform of the complicated U.S. drug-pricing system seems ever more likely. 

One part of the system that the Trump administration wants to overhaul are the secret rebates that drug makers, insurers, and middlemen negotiate behind closed doors.

Replacements for those rebates, however, could have unintended consequences, says a nonprofit watchdog group that in the past decade has been a key amplifier of the drug-price debate.

The watchdog, the Institute for Clinical and Economic Review of Boston, typically weighs in on the value of a single drug, often—but not always—with a skeptical eye on the price set by the drug maker.

Read Xconomy National article